What is the recommended pharmacologic and non‑pharmacologic management for a 64‑year‑old patient with osteoporosis (lumbar spine T‑score –2.5, femoral neck T‑score –2.3, total hip T‑score –1.3) and a FRAX 10‑year major osteoporotic fracture risk of 10.4%?

Recommended Management for Osteoporosis with T-score -2.5 and Moderate FRAX Risk

This patient meets clear criteria for pharmacologic treatment and should be started on oral bisphosphonate therapy (alendronate or risedronate) as first-line treatment, combined with calcium 1000-1200 mg/day and vitamin D 800 IU/day supplementation, along with weight-bearing exercise and fall prevention strategies. 1

Rationale for Pharmacologic Treatment

Your patient definitively qualifies for pharmacologic intervention based on multiple criteria:

• T-score of -2.5 at the lumbar spine confirms WHO-defined osteoporosis, which is an absolute indication for treatment 1
• The International Society for Clinical Densitometry guidelines explicitly recommend pharmacologic therapy for patients with T-score ≤-2.5 at spine, femoral neck, or total hip 1
• While the FRAX score shows "moderate" risk (10.4% major osteoporotic fracture, 2.0% hip fracture), the T-score criterion alone mandates treatment regardless of FRAX 1

Important caveat: The concerning 8.0% decrease in left total hip BMD since the last scan signals active bone loss and further supports immediate intervention. 1

First-Line Pharmacologic Treatment

Oral Bisphosphonates (Preferred)

Alendronate and risedronate are first-choice agents because they:

• Reduce vertebral fractures by 50-70%, non-vertebral fractures by 20-30%, and hip fractures by ~40% 1, 2
• Are well-tolerated, available as generics (low cost), and have extensive clinical experience 1
• Have high-quality evidence demonstrating reduction in vertebral, non-vertebral, AND hip fractures 1

Dosing options: 1

• Alendronate: 10 mg daily OR 70 mg weekly
• Risedronate: 5 mg daily OR 35 mg weekly OR 150 mg monthly

Treatment duration: Prescribe for 5 years initially, then reassess fracture risk to determine if continuation or drug holiday is appropriate 1

Alternative Agents (If Bisphosphonates Not Tolerated)

If oral bisphosphonates cause gastrointestinal intolerance, esophageal abnormalities, or inability to comply with dosing requirements (standing/sitting upright for 30 minutes): 1

• Zoledronic acid (IV): 5 mg annually
• Denosumab (subcutaneous): 60 mg every 6 months

Critical warning about denosumab: If denosumab is ever started and then discontinued, there is a pronounced rebound effect starting 7 months after the last injection that can cause clusters of vertebral fractures. Transition to bisphosphonates is mandatory if stopping denosumab. 2, 3

Essential Non-Pharmacologic Interventions

Calcium and Vitamin D Supplementation

Mandatory for all patients on osteoporosis therapy: 1

• Calcium: 1000-1200 mg/day total intake (dietary plus supplementation if needed)
• Vitamin D: 800 IU/day
• Target serum vitamin D level ≥20 ng/mL (50 nmol/L) 1

This combination reduces non-vertebral fractures by 15-20% and falls by 20% 1

Avoid high-dose pulse vitamin D as it increases fall risk 1

Lifestyle Modifications

Weight-bearing and muscle-strengthening exercise: 1, 4

• Muscle resistance exercises (squats, push-ups)
• Balance training (heel raises, standing on one foot)
• These interventions reduce fall risk and maintain bone health

Smoking cessation and alcohol limitation: 1

• Both negatively affect BMD, bone quality, and fall risk

Fall Prevention Program

Multidimensional fall prevention is critical given this patient's back pain and osteoporosis: 1

• Home safety assessment
• Balance training (long-term continuation recommended)
• Review medications that increase fall risk
• Address vision and gait problems

Monitoring Strategy

Do NOT Monitor BMD During Initial Treatment

Current evidence shows no benefit for BMD monitoring during the first 5 years of treatment 1

• Patients benefit from fracture reduction even if BMD doesn't increase or actually decreases 1
• Monitoring bone turnover markers or repeat DXA during active treatment is not recommended for the first 5 years 1

After 5 Years: Reassess

• Evaluate fracture risk profile
• Consider drug holiday for oral bisphosphonates (1-2 years) to minimize atypical femoral fracture risk 2
• Continue treatment if patient remains high risk 1

Common Pitfalls to Avoid

1. Don't delay treatment waiting for FRAX thresholds when T-score already meets osteoporosis criteria (≤-2.5) 1

2. Don't prescribe calcium alone without vitamin D and pharmacologic therapy—calcium alone has no demonstrated fracture reduction effect 1

3. Don't forget proper bisphosphonate administration instructions: Take on empty stomach with full glass of water, remain upright for 30 minutes, no food/drink for 30 minutes 1

4. Don't ignore the back pain: Evaluate for possible vertebral compression fractures, which would elevate this patient to very high fracture risk 1, 4

5. Don't stop denosumab without transition therapy if that agent is ever used 2, 3

Special Consideration: Address the Back Pain

Vertebral fractures may be present and would change management: 4

• Consider vertebral fracture assessment (VFA) or spine radiographs
• If vertebral fractures are confirmed, this patient becomes very high risk and anabolic therapy (teriparatide, abaloparatide, or romosozumab) should be considered before or instead of bisphosphonates 4, 2